Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Patrycja Gazinska"'
Autor:
Thomas Hardiman, Patrycja Gazinska, Jelmar Quist, Sarah E Pinder, Fangfang Liu, Anita Grigoriadis
Publikováno v:
Cancer Research. 81:PS6-36
Purpose: To assess the frequency and prognostic relevance of germinal centres (GC) in cancer-free axillary lymph nodes (ALNs), in relation to stromal tumour-infiltrating lymphocytes (sTILs) and the presence of tertiary lymphoid structures (TLS) in th
Autor:
Cheryl Gillett, C. Toms, Julie Owen, Sarah Kernaghan, Holly Tovey, Andrew Tutt, Patrycja Gazinska, Judith M Bliss, Sarah Maguire, Sabine C. Linn, Maggie C.U. Cheang, Orsolya Sipos, Sarah E Pinder, Salpie Nowinski, Syed Haider, Nick Orr, Anita Grigoriadis, Jelmar Quist
Publikováno v:
Sipos, O, Tovey, H, Quist, J, Hyder, S, Nowinski, S, Gazinska, P, Kernaghan, S, Toms, C, Maguire, S, Orr, N, Linn, S, Owen, J, Gillett, C, Pinder, S, Bliss, J, Tutt, A, Cheang, M C U & Grigoriadis, A 2021, ' Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer : the TNT trial ', Annals of Oncology, vol. 32, no. 1, pp. 58-65 . https://doi.org/10.1016/j.annonc.2020.10.475
Annals of Oncology
Annals of Oncology
Background In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider pa
Autor:
Kailiang Wu, Xiaojing Guo, Roberto Salgado, Fangfang Liu, Anita Grigoriadis, Arnie Purushotham, Tony Ng, Jelmar Quist, Sarah E Pinder, Thomas Hardiman, Patrycja Gazinska
Publikováno v:
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
npj Breast Cancer, Vol 7, Iss 1, Pp 1-10 (2021)
The level of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative (TNBC) and HER2-positive breast cancers convey prognostic information. The importance of systemic immunity to local immunity is unknown in breast cancer. We previously dem
Autor:
Duncan Wheatley, A. Thompson, Steven Gendreau, Sirwan Hadad, Louise Lim, Lackner, C Zummit, Arnie Purushotham, Nigel J Bundred, Paul N. Mainwaring, Darren Korbie, A Shia, Kelly Mousa, Carol L. O'brien, Robert G. Price, E.J. Macaskill, Peter Schmid, Jennifer J. Hu, Matt Trau, S. Pinder, S-J Sarker, Patrycja Gazinska, Timothy R. Wilson
Publikováno v:
Cancer Research. 79:P2-08
Background: Although preclinical data suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance, results from randomized clinical trials have failed to identify a subgroup of patients that derive a substantial benefit. Thi
Autor:
Sarah Kernaghan, Judith M Bliss, Kirsten Timms, Mcu Cheang, Holly Tovey, Andrew Tutt, Syed Haider, A Grigoriadis, Salpie Nowinski, O Sipos, C. Toms, Jerry S. Lanchbury, Sabine C. Linn, Sarah E Pinder, Patrycja Gazinska, Investigators, Jelmar Quist
Publikováno v:
Cancer Research. 79:P1-06
Background A distinctive trait of triple negative breast cancer (TNBC) is the acquisition of genome wide highly aberrant copy number states, which is more evident in metastatic settings. The level of copy number alterations can be characterized by qu
Autor:
Jane Macaskill, Alastair M. Thompson, Gemma Earl, Duncan Wheatley, Matt Trau, Patrycja Gazinska, Hannah Butler, Shah-Jalal Sarker, Timothy R. Wilson, Charles Zammit, Peter Schmid, A Shia, Louise Lim, Mark R. Lackner, Arnie Purushotham, Darren Korbie, Natalie Woodman, Sarah E Pinder, Sirwan Hadad, Paul N. Mainwaring, Peter J. Parker, Jennifer Hu, Steven Gendreau, Mika K. Derynck, Nigel J Bundred, Robert G. Price
Publikováno v:
Journal of Clinical Oncology. 34:1987-1994
Purpose Preclinical data support a key role for the PI3K pathway in estrogen receptor–positive breast cancer and suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance. This preoperative window study assessed whether
Autor:
Michel Eisenblaetter, Gregory Weitsman, Mark Battle, Imtiaz Khan, Grethe Tang Dalsgaard, Graeme McRobbie, Susan Hoppmann, James Monypenny, Patrycja Gazinska, Wulan Wulaningsih, Appitha Arulappu, Sven Macholl, Myria Galazi, Tony Ng
Publikováno v:
Arulappu, A, Battle, M, Eisenblaetter, M, McRobbie, G, Khan, I, Monypenny, J, Weitsman, G, Galazi, M, Hoppmann, S, Gazinska, P, Wulaningsih, W, Dalsgaard, G T, Macholl, S & Ng, T 2016, ' c-Met PET Imaging Detects Early-Stage Locoregional Recurrence of Basal-Like Breast Cancer ', Journal of Nuclear Medicine, vol. 57, no. 5, pp. 765-70 . https://doi.org/10.2967/jnumed.115.164384
Locoregional recurrence of breast cancer poses significant clinical problems because of frequent inoperability once the chest wall is involved. Early detection of recurrence by molecular imaging agents against therapeutically targetable receptors, su
Autor:
Orsolya Sipos, Charles M. Perou, Sarah Kernaghan, Maggie C.U. Cheang, Anita Grigoriadis, Joel S. Parker, Richard D. Kennedy, Judith M Bliss, Sarah E Pinder, Holly Tovey, Patrycja Gazinska, Katherine A. Hoadley, Syed Haider, Lucy Kilburn, Andrew Tutt
Publikováno v:
Journal of Clinical Oncology. 38:1074-1074
1074 Background: In the Triple Negative Trial we observed no improved response rate (RR) to C over D in aTNBC [Tutt et al, Nat Med 2018], but we did in BRCA1/2 mutated (mut) patients (pts). We hypothesise tumors with other aberrant DNA damage respons
Autor:
Patrycja Gazinska, Mitchell Dowsett, Lisa Fox, Adam Shaw, Nazneen Rahman, Vandna Shah, Jyoti Parikh, Andrew M Wardley, Kirsten Timms, Rebecca Roylance, Julie Owen, Catherine Harper-Wynne, Sophie Barrett, Peter Barrett-Lee, Ian E. Smith, Cheryl Gillett, James M. Flanagan, Robert S. Brown, Jacinta Abraham, Mark Harries, Holly Tovey, Katherine A. Hoadley, Lucy Kilburn, Matthew Hatton, Judith M Bliss, Alexander Gutin, Charles M. Perou, Sarah Kernaghan, Anita Grigoriadis, Alan Ashworth, Maggie C.U. Cheang, Gregory C. Wilson, Paul Ellis, Sarah E Pinder, Peter J. Parker, Andrew Tutt, Jerry S. Lanchbury, Stephen Chan
Publikováno v:
Tutt, A, Tovey, H, Cheang, M C U, Kernaghan, S, Kilburn, L, Gazinska, P, Owen, J, Abraham, J, Barrett, S, Barrett-Lee, P, Brown, R, Chan, S, Dowsett, M, Flanagan, J M, Fox, L, Grigoriadis, A, Gutin, A, Harper-Wynne, C, Hatton, M Q, Hoadley, K A, Parikh, J, Parker, P, Perou, C M, Roylance, R, Shah, V, Shaw, A, Smith, I E, Timms, K M, Wardley, A M, Wilson, G, Gillett, C, Lanchbury, J S, Ashworth, A, Rahman, N, Harries, M, Ellis, P, Pinder, S E, Bliss, J M 2018, ' Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups : the TNT Trial ', Nature Medicine, vol. 24, no. 5, pp. 628–637 . https://doi.org/10.1038/s41591-018-0009-7
Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) and causing genomic instability. HR also repairs DNA lesions caused by platinum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12370f4abedb61193f5a6afd891a308c
https://eprints.whiterose.ac.uk/140715/3/TNT_manuscript_Nat_Med_post_review.pdf
https://eprints.whiterose.ac.uk/140715/3/TNT_manuscript_Nat_Med_post_review.pdf
Autor:
Fiona M. Blows, Sarah-Jane Dawson, Jelle Wesseling, Ian W. Brock, William J. Howat, Wilma E. Mesker, Veli-Matti Kosma, Penny Coulson, Leigh-Anne McDuffus, Rainer Fagerholm, Sarah E Pinder, Carolien H.M. van Deurzen, Angela Cox, Lorna Morris, Malcolm W.R. Reed, Arto Mannermaa, Louise Jones, Carl Blomqvist, Reijo Sironen, Daniel W. Visscher, Vesa Kataja, Annegien Broeks, Janet E. Olson, Simon S. Cross, Patrycja Gazinska, Mark E. Sherman, Marjanka K. Schmidt, Joyce Sanders, Manjeet K. Bolla, Jonine D. Figueroa, Caroline M. Seyaneve, Paul D.P. Pharoah, Elena Provenzano, Douglas F. Easton, Päivi Heikkilä, Mark N. Brook, Elinor J. Sawyer, Jose Ignacio Arias Perez, Javier Benítez, Heli Nevanlinna, Montserrat Garcia-Closas, Peter Devillee, Jolanta Lissowska, Primitiva Menéndez, Carlos Caldas, Louise A. Brinton, Nicola Johnson, Jodi Miller, Frances Daley, Fergus J. Couch, H. Raza Ali, Antoinette Hollestelle
Publikováno v:
The Journal of Pathology: Clinical Research. 1:18-32
Breast cancer risk factors and clinical outcomes vary by tumour marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need for high throughput, standard